Guo Yu

Dr. Guo Yu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in Gut
Verified
Journal Article
Open access
PDF file
GLGuo-Fu Li
Guo-Fu Li
XAXiao-Xiao An
Xiao-Xiao An
YYYichao Yu
Yichao Yu
LJLi-Rong Jiao
Li-Rong Jiao
DCDaniele Canarutto
Daniele Canarutto
Yin XiaoYin Xiao
Yin Xiao

15 February 2019 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
GLGuo-Fu Li
Guo-Fu Li
QZQing-Shan Zheng
Qing-Shan Zheng
YYYichao Yu
Yichao Yu
WZWei Zhong
Wei Zhong
HZHong-Hao Zhou
Hong-Hao Zhou
HDHartmut Derendorf
Hartmut Derendorf

12 January 2024 in BMC Medicine
Verified
Journal Article
Open access
PDF file
HSHanqiao Shao
Hanqiao Shao
MZMingye Zhao
Mingye Zhao
AGAi-Jia Guan
Ai-Jia Guan
TSTaihang Shao
Taihang Shao
DZDachuang Zhou
Dachuang Zhou
WTWenxi Tang
Wenxi Tang
Background: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 −) advanced breast cancer is a prevalent subtype among postmenopausal women. Despite the growing number of randomized clinical trials (RCTs) exploring this topic, the efficacy and safety of first-line and second/further-line treatments remain uncertain. Accordingly, our aim was to conduct a comprehensive evaluation of the efficacy and safety of these therapies through network meta-analysis.Methods: RCTs were identified by searching Pubmed, Embase, and major cancer conferences. The efficacy of interventions was assessed using the hazard ratios (HRs) of progression-free survival (PFS) and overall survival (OS), while safety was indicated by the incidence of any grade adverse events (AEs), grade 3–5 AEs, AEs leading to treatment discontinuation, and AEs leading to death. Both time-variant HRs fractional polynomial models and time-invariant HRs Cox-proportional hazards models were considered for handling time-to-event data. Safety indicators were analyzed using Bayesian network meta-analysis. Additionally, subgroup analyses were conducted based on patient characteristics.Results: A total of 41 RCTs (first-line 17, second/further-lines 27) were included in the analysis. For first-line treatment, the addition of Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to endocrine therapy significantly improved therapeutic efficacy in terms of both PFS and OS, demonstrating the best performance across all mechanisms. Specifically, the combination of Abemaciclib and Letrozole demonstrated the most favorable performance in terms of PFS, while Ribociclib plus Fulvestrant yielded the best outcomes in OS. Incorporating the immune checkpoint inhibitor Avelumab into the regimen with CDK4/6 inhibitors and selective estrogen receptor degraders significantly enhanced both PFS and OS in second-line or later treatments. Regarding safety, endocrine monotherapy performed well. Regarding safety, endocrine monotherapy performed well. There is mounting evidence suggesting that most CDK4/6 inhibitors may demonstrate poorer performance with respect to hematologic AEs. However, additional evidence is required to further substantiate these findings.Conclusions: CDK4/6 inhibitors, combined with endocrine therapy, are pivotal in first-line treatment due to their superior efficacy and manageable AEs. For second/further-line treatment, adding immune checkpoint inhibitors to CDK4/6 inhibitors plus endocrine therapy may produce promising results. However, to reduce the results’ uncertainty, further trials comparing these novel treatments are warranted.Trial registration: Registration number: PROSPERO (CRD42022377431).

1 October 2021 in Clinical Therapeutics
Verified
Journal Article
Closed access
CLChen-Xi Lu
Chen-Xi Lu
XAXiao-Xiao An
Xiao-Xiao An
YYYichao Yu
Yichao Yu
LJLi-Rong Jiao
Li-Rong Jiao
DCDaniele Canarutto
Daniele Canarutto
GYGuo Yu
Guo Yu

23 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
YYYang Yu
Yang Yu
YLYu-Ren Liu
Yu-Ren Liu
FLFan-Ming Luo
Fan-Ming Luo
WTWei-Wei Tu
Wei-Wei Tu
DZDe-Chuan Zhan
De-Chuan Zhan
ZZZhi-Hua Zhou
Zhi-Hua Zhou
Background: Mounting evidence suggests that there is an undetected pool of COVID-19 asymptomatic but infectious cases. Estimating the number of asymptomatic infections has been crucial to understand the virus and contain its spread, which is, however, hard to be accurately counted. Methods: We propose an approach of machine learning based fine-grained simulator (ML-Sim), which integrates multiple practical factors including disease progress in the incubation period, cross-region population movement, undetected asymptomatic patients, and prevention and containment strength. The interactions among these factors are modeled by virtual transmission dynamics with several undetermined parameters, which are determined from epidemic data by machine learning techniques. When MLSim learns to match the real data closely, it also models the number of asymptomatic patients. MLSim is learned from the open Chinese global epidemic data. Findings: MLSim showed better forecast accuracy than the SEIR and LSTM-based prediction models. The MLSim learned from the data of China’s mainland reveals that there could have been 150,408 (142,178-157,417) asymptomatic and had self-healed patients, which is 65% (64% – 65%) of the inferred total infections including undetected ones. The numbers of asymptomatic but infectious patients on April 15, 2020, were inferred as, Italy: 41,387 (29,037 – 57,151), Germany: 21,118 (11,484 – 41,646), USA: 354,657 (277,641 – 495,128), France: 40,379 (10,807 – 186,878), and UK: 144,424 (127,215 – 171,930). To control the virus transmission, the containment measures taken by the government were crucial. The learned MLSim also reveals that if the date of containment measures in China’s mainland was postponed for 1, 3, 5, and 7 days later than Jan. 23, there would be 109,039 (129%), 183,930 (218%), 313,342 (371%), 537,555 (637%) confirmed cases on June 12. Conclusions: Machine learning based fine-grained simulators can better model the complex real-world disease transmission process, and thus can help decision-making of balanced containment measures. The simulator also revealed the potential great number of undetected asymptomatic infections, which poses a great risk to the virus containment. Funding: National Natural Science Foundation of China.

10 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GLGuo-Fu Li
Guo-Fu Li
YQYu-Wei Qiao
Yu-Wei Qiao
AGAi-Jia Guan
Ai-Jia Guan
GYGuo Yu
Guo Yu